Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Timothy PapalucaStuart K RobertsSimone I StrasserKatherine A StuartGeoffrey FarrellGerry MacQuillanGregory J DoreAmanda J WadeJacob GeorgeSimon HazeldineJames O'BeirneAlan WiggLeslie FisherBruce McGarityRohit SawhneyMarie SinclairJames ThomasIvan ValiozisMartin WeltmanMark WilsonAidan WoodwardGolo AhlenstielMazhar HaqueMiriam LevyEmily PrewettWilliam SievertSiddharth SoodEdmund TseZina ValaydonScott BowdenMark W DouglasKate NewJacinta O'KeefeMargaret HellardJoseph DoyleMark StooveAlexander J ThompsonPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
This real-world study confirms high efficacy of SOF/VEL/VOX for the treatment of difficult-to-cure NS5A-inhibitor experienced patients, including those with GT3 and cirrhosis. Treatment was well tolerated in most; however, serious AEs can occur in those with advanced liver disease.